nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—CYP1B1—prostate cancer	0.0796	0.276	CbGaD
Erlotinib—EGFR—prostate cancer	0.0751	0.26	CbGaD
Erlotinib—CYP3A5—prostate cancer	0.0634	0.22	CbGaD
Erlotinib—CYP1A1—prostate cancer	0.043	0.149	CbGaD
Erlotinib—NR1I2—Ethinyl Estradiol—prostate cancer	0.0398	0.0897	CbGbCtD
Erlotinib—CYP3A4—prostate cancer	0.0274	0.0951	CbGaD
Erlotinib—NR1I2—Estradiol—prostate cancer	0.0256	0.0578	CbGbCtD
Erlotinib—CYP1B1—Flutamide—prostate cancer	0.0236	0.0531	CbGbCtD
Erlotinib—SLCO2B1—Estrone—prostate cancer	0.0197	0.0444	CbGbCtD
Erlotinib—ORM1—Abiraterone—prostate cancer	0.0184	0.0414	CbGbCtD
Erlotinib—CYP1B1—Estrone—prostate cancer	0.017	0.0384	CbGbCtD
Erlotinib—EGFR—Docetaxel—prostate cancer	0.0168	0.0379	CbGbCtD
Erlotinib—NR1I2—Docetaxel—prostate cancer	0.0153	0.0345	CbGbCtD
Erlotinib—SLCO2B1—Conjugated Estrogens—prostate cancer	0.0129	0.0291	CbGbCtD
Erlotinib—SLCO2B1—Estradiol—prostate cancer	0.0113	0.0255	CbGbCtD
Erlotinib—CYP1A1—Flutamide—prostate cancer	0.0103	0.0233	CbGbCtD
Erlotinib—CYP1B1—Mitoxantrone—prostate cancer	0.0101	0.0228	CbGbCtD
Erlotinib—CYP1B1—Estradiol—prostate cancer	0.00978	0.0221	CbGbCtD
Erlotinib—UGT1A1—Estradiol—prostate cancer	0.00846	0.0191	CbGbCtD
Erlotinib—ABCG2—Cabazitaxel—prostate cancer	0.00829	0.0187	CbGbCtD
Erlotinib—ABCG2—Estrone—prostate cancer	0.0081	0.0183	CbGbCtD
Erlotinib—ALB—Abiraterone—prostate cancer	0.00772	0.0174	CbGbCtD
Erlotinib—CYP1A1—Estrone—prostate cancer	0.00747	0.0169	CbGbCtD
Erlotinib—CYP2C8—Nilutamide—prostate cancer	0.0072	0.0162	CbGbCtD
Erlotinib—CYP3A5—Flutamide—prostate cancer	0.00621	0.014	CbGbCtD
Erlotinib—CYP2C8—Abiraterone—prostate cancer	0.00597	0.0135	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—prostate cancer	0.00584	0.0132	CbGbCtD
Erlotinib—ALB—Estrone—prostate cancer	0.00558	0.0126	CbGbCtD
Erlotinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00556	0.0125	CbGbCtD
Erlotinib—UGT1A1—Etoposide—prostate cancer	0.00552	0.0125	CbGbCtD
Erlotinib—ABCG2—Conjugated Estrogens—prostate cancer	0.0053	0.0119	CbGbCtD
Erlotinib—ABCG2—Mitoxantrone—prostate cancer	0.00482	0.0109	CbGbCtD
Erlotinib—ABCG2—Estradiol—prostate cancer	0.00465	0.0105	CbGbCtD
Erlotinib—CYP1A2—Flutamide—prostate cancer	0.00462	0.0104	CbGbCtD
Erlotinib—CYP2D6—Bicalutamide—prostate cancer	0.00459	0.0104	CbGbCtD
Erlotinib—CYP3A5—Cabazitaxel—prostate cancer	0.00459	0.0104	CbGbCtD
Erlotinib—ABCB1—Estramustine—prostate cancer	0.00453	0.0102	CbGbCtD
Erlotinib—CYP3A5—Estrone—prostate cancer	0.00449	0.0101	CbGbCtD
Erlotinib—CYP2C8—Cabazitaxel—prostate cancer	0.00441	0.00995	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—prostate cancer	0.00436	0.00983	CbGbCtD
Erlotinib—CYP1A1—Estradiol—prostate cancer	0.00429	0.00968	CbGbCtD
Erlotinib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00384	0.00867	CbGbCtD
Erlotinib—CYP2D6—Abiraterone—prostate cancer	0.00381	0.00858	CbGbCtD
Erlotinib—CYP1A2—Estrone—prostate cancer	0.00334	0.00753	CbGbCtD
Erlotinib—ALB—Estradiol—prostate cancer	0.00321	0.00723	CbGbCtD
Erlotinib—ABCG2—Etoposide—prostate cancer	0.00304	0.00685	CbGbCtD
Erlotinib—ABCB1—Cabazitaxel—prostate cancer	0.00299	0.00674	CbGbCtD
Erlotinib—CYP3A4—Bicalutamide—prostate cancer	0.00292	0.00659	CbGbCtD
Erlotinib—ABCB1—Estrone—prostate cancer	0.00292	0.00658	CbGbCtD
Erlotinib—ABCG2—Docetaxel—prostate cancer	0.00278	0.00627	CbGbCtD
Erlotinib—ALB—Prednisone—prostate cancer	0.00276	0.00622	CbGbCtD
Erlotinib—CYP3A4—Estramustine—prostate cancer	0.00271	0.00612	CbGbCtD
Erlotinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.0026	0.00587	CbGbCtD
Erlotinib—CYP3A5—Estradiol—prostate cancer	0.00258	0.00581	CbGbCtD
Erlotinib—CYP2C8—Estradiol—prostate cancer	0.00248	0.00559	CbGbCtD
Erlotinib—CYP3A4—Abiraterone—prostate cancer	0.00242	0.00546	CbGbCtD
Erlotinib—CYP3A4—Flutamide—prostate cancer	0.00242	0.00546	CbGbCtD
Erlotinib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00218	0.00493	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—prostate cancer	0.00207	0.00467	CbGbCtD
Erlotinib—CYP1A2—Estradiol—prostate cancer	0.00192	0.00432	CbGbCtD
Erlotinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00191	0.00431	CbGbCtD
Erlotinib—UGT1A1—urine—prostate cancer	0.00184	0.0393	CbGeAlD
Erlotinib—CYP3A4—Cabazitaxel—prostate cancer	0.00179	0.00404	CbGbCtD
Erlotinib—CYP3A4—Estrone—prostate cancer	0.00175	0.00395	CbGbCtD
Erlotinib—ABCB1—Mitoxantrone—prostate cancer	0.00174	0.00392	CbGbCtD
Erlotinib—CYP3A5—Etoposide—prostate cancer	0.00168	0.00379	CbGbCtD
Erlotinib—ABCB1—Estradiol—prostate cancer	0.00168	0.00378	CbGbCtD
Erlotinib—CYP2C8—Etoposide—prostate cancer	0.00162	0.00365	CbGbCtD
Erlotinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00156	0.00352	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—prostate cancer	0.00154	0.00347	CbGbCtD
Erlotinib—ABCB1—Prednisone—prostate cancer	0.00144	0.00325	CbGbCtD
Erlotinib—JAK3—prostate gland—prostate cancer	0.00133	0.0283	CbGeAlD
Erlotinib—EPHA6—prostate gland—prostate cancer	0.00133	0.0283	CbGeAlD
Erlotinib—CYP1A2—Etoposide—prostate cancer	0.00125	0.00282	CbGbCtD
Erlotinib—TNK1—prostate gland—prostate cancer	0.00122	0.026	CbGeAlD
Erlotinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00114	0.00258	CbGbCtD
Erlotinib—ABCB1—Etoposide—prostate cancer	0.0011	0.00247	CbGbCtD
Erlotinib—CYP3A4—Mitoxantrone—prostate cancer	0.00104	0.00235	CbGbCtD
Erlotinib—CYP3A4—Estradiol—prostate cancer	0.001	0.00227	CbGbCtD
Erlotinib—ABCB1—Docetaxel—prostate cancer	0.001	0.00226	CbGbCtD
Erlotinib—ABL2—prostate gland—prostate cancer	0.001	0.0213	CbGeAlD
Erlotinib—EGFR—prostate gland—prostate cancer	0.000976	0.0208	CbGeAlD
Erlotinib—PIP4K2C—prostate gland—prostate cancer	0.000947	0.0202	CbGeAlD
Erlotinib—ULK3—prostate gland—prostate cancer	0.000904	0.0193	CbGeAlD
Erlotinib—CYP3A4—Prednisone—prostate cancer	0.000864	0.00195	CbGbCtD
Erlotinib—MKNK1—prostate gland—prostate cancer	0.000851	0.0181	CbGeAlD
Erlotinib—TNK1—urethra—prostate cancer	0.000817	0.0174	CbGeAlD
Erlotinib—CYP1A2—urine—prostate cancer	0.000816	0.0174	CbGeAlD
Erlotinib—SLK—prostate gland—prostate cancer	0.000806	0.0172	CbGeAlD
Erlotinib—PIP4K2C—seminal vesicle—prostate cancer	0.000801	0.0171	CbGeAlD
Erlotinib—ULK3—seminal vesicle—prostate cancer	0.000764	0.0163	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—prostate cancer	0.000747	0.00168	CbGbCtD
Erlotinib—HIPK4—testis—prostate cancer	0.00074	0.0158	CbGeAlD
Erlotinib—LTK—testis—prostate cancer	0.000732	0.0156	CbGeAlD
Erlotinib—CYP2D6—Doxorubicin—prostate cancer	0.000704	0.00159	CbGbCtD
Erlotinib—STK10—prostate gland—prostate cancer	0.000701	0.0149	CbGeAlD
Erlotinib—SLK—seminal vesicle—prostate cancer	0.000681	0.0145	CbGeAlD
Erlotinib—UGT1A1—prostate gland—prostate cancer	0.000662	0.0141	CbGeAlD
Erlotinib—CYP3A4—Etoposide—prostate cancer	0.000656	0.00148	CbGbCtD
Erlotinib—PIP4K2C—urethra—prostate cancer	0.000634	0.0135	CbGeAlD
Erlotinib—AURKC—testis—prostate cancer	0.000632	0.0135	CbGeAlD
Erlotinib—MAP2K5—prostate gland—prostate cancer	0.000626	0.0133	CbGeAlD
Erlotinib—Vandetanib—BMPR1B—prostate cancer	0.000625	0.154	CrCbGaD
Erlotinib—Vandetanib—IRAK4—prostate cancer	0.000625	0.154	CrCbGaD
Erlotinib—ULK3—urethra—prostate cancer	0.000605	0.0129	CbGeAlD
Erlotinib—CYP3A4—Docetaxel—prostate cancer	0.0006	0.00135	CbGbCtD
Erlotinib—Gefitinib—IRAK4—prostate cancer	0.000594	0.146	CrCbGaD
Erlotinib—CYP3A4—urine—prostate cancer	0.000591	0.0126	CbGeAlD
Erlotinib—JAK3—testis—prostate cancer	0.000585	0.0125	CbGeAlD
Erlotinib—EPHA6—testis—prostate cancer	0.000585	0.0125	CbGeAlD
Erlotinib—CYP2D6—urine—prostate cancer	0.000581	0.0124	CbGeAlD
Erlotinib—MKNK1—urethra—prostate cancer	0.00057	0.0121	CbGeAlD
Erlotinib—FLT3—bone marrow—prostate cancer	0.00054	0.0115	CbGeAlD
Erlotinib—SLK—urethra—prostate cancer	0.000539	0.0115	CbGeAlD
Erlotinib—TNK1—testis—prostate cancer	0.000537	0.0114	CbGeAlD
Erlotinib—MAP3K19—testis—prostate cancer	0.000532	0.0113	CbGeAlD
Erlotinib—LTK—lymph node—prostate cancer	0.000531	0.0113	CbGeAlD
Erlotinib—MAP2K5—seminal vesicle—prostate cancer	0.000529	0.0113	CbGeAlD
Erlotinib—ORM1—prostate gland—prostate cancer	0.000508	0.0108	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—prostate cancer	0.000488	0.0104	CbGeAlD
Erlotinib—SLCO2B1—prostate gland—prostate cancer	0.000487	0.0104	CbGeAlD
Erlotinib—ABL1—prostate gland—prostate cancer	0.000483	0.0103	CbGeAlD
Erlotinib—STK10—renal system—prostate cancer	0.000477	0.0102	CbGeAlD
Erlotinib—ULK3—bone marrow—prostate cancer	0.000466	0.00992	CbGeAlD
Erlotinib—FLT3—testis—prostate cancer	0.000462	0.00983	CbGeAlD
Erlotinib—AURKC—lymph node—prostate cancer	0.000458	0.00976	CbGeAlD
Erlotinib—UGT1A1—renal system—prostate cancer	0.000451	0.00961	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—prostate cancer	0.000447	0.00101	CbGbCtD
Erlotinib—ABL2—testis—prostate cancer	0.000441	0.00939	CbGeAlD
Erlotinib—MKNK1—bone marrow—prostate cancer	0.000438	0.00934	CbGeAlD
Erlotinib—EGFR—testis—prostate cancer	0.00043	0.00916	CbGeAlD
Erlotinib—JAK3—lymph node—prostate cancer	0.000424	0.00904	CbGeAlD
Erlotinib—MAP2K5—urethra—prostate cancer	0.000419	0.00892	CbGeAlD
Erlotinib—PIP4K2C—testis—prostate cancer	0.000417	0.00888	CbGeAlD
Erlotinib—SLK—bone marrow—prostate cancer	0.000415	0.00884	CbGeAlD
Erlotinib—MKNK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000413	0.187	CbGdCrCtD
Erlotinib—CYP1B1—prostate gland—prostate cancer	0.000409	0.00871	CbGeAlD
Erlotinib—ABL1—seminal vesicle—prostate cancer	0.000408	0.0087	CbGeAlD
Erlotinib—ULK3—testis—prostate cancer	0.000398	0.00848	CbGeAlD
Erlotinib—TNK1—lymph node—prostate cancer	0.000389	0.0083	CbGeAlD
Erlotinib—MKNK1—testis—prostate cancer	0.000375	0.00798	CbGeAlD
Erlotinib—STK10—bone marrow—prostate cancer	0.000361	0.00769	CbGeAlD
Erlotinib—SLK—testis—prostate cancer	0.000355	0.00756	CbGeAlD
Erlotinib—MKNK1—Estradiol—Estramustine—prostate cancer	0.000351	0.159	CbGdCrCtD
Erlotinib—FLT3—lymph node—prostate cancer	0.000335	0.00713	CbGeAlD
Erlotinib—SLCO2B1—renal system—prostate cancer	0.000332	0.00707	CbGeAlD
Erlotinib—ABL1—renal system—prostate cancer	0.000329	0.00701	CbGeAlD
Erlotinib—ABL1—urethra—prostate cancer	0.000323	0.00688	CbGeAlD
Erlotinib—ABL2—lymph node—prostate cancer	0.000319	0.00681	CbGeAlD
Erlotinib—EGFR—lymph node—prostate cancer	0.000312	0.00664	CbGeAlD
Erlotinib—STK10—testis—prostate cancer	0.000309	0.00657	CbGeAlD
Erlotinib—Gefitinib—CHEK2—prostate cancer	0.000306	0.0754	CrCbGaD
Erlotinib—ABCG2—prostate gland—prostate cancer	0.000304	0.00648	CbGeAlD
Erlotinib—PIP4K2C—lymph node—prostate cancer	0.000302	0.00644	CbGeAlD
Erlotinib—ULK3—lymph node—prostate cancer	0.000289	0.00615	CbGeAlD
Erlotinib—Vandetanib—ERBB3—prostate cancer	0.000287	0.0707	CrCbGaD
Erlotinib—CYP3A5—prostate gland—prostate cancer	0.000282	0.00602	CbGeAlD
Erlotinib—MKNK1—Estradiol—Estrone—prostate cancer	0.000279	0.126	CbGdCrCtD
Erlotinib—CYP1B1—renal system—prostate cancer	0.000279	0.00593	CbGeAlD
Erlotinib—MAP2K5—testis—prostate cancer	0.000276	0.00587	CbGeAlD
Erlotinib—Gefitinib—ERBB3—prostate cancer	0.000273	0.0672	CrCbGaD
Erlotinib—MKNK1—lymph node—prostate cancer	0.000272	0.00579	CbGeAlD
Erlotinib—ORM1—bone marrow—prostate cancer	0.000262	0.00558	CbGeAlD
Erlotinib—ABCG2—seminal vesicle—prostate cancer	0.000257	0.00548	CbGeAlD
Erlotinib—SLK—lymph node—prostate cancer	0.000257	0.00548	CbGeAlD
Erlotinib—ABL1—bone marrow—prostate cancer	0.000249	0.0053	CbGeAlD
Erlotinib—MKNK1—Estradiol—Conjugated Estrogens—prostate cancer	0.000246	0.111	CbGdCrCtD
Erlotinib—Vandetanib—PDGFRB—prostate cancer	0.000237	0.0585	CrCbGaD
Erlotinib—STK10—lymph node—prostate cancer	0.000224	0.00477	CbGeAlD
Erlotinib—SLCO2B1—testis—prostate cancer	0.000214	0.00457	CbGeAlD
Erlotinib—CYP2C8—renal system—prostate cancer	0.000213	0.00454	CbGeAlD
Erlotinib—ABL1—testis—prostate cancer	0.000213	0.00453	CbGeAlD
Erlotinib—CYP1A1—epithelium—prostate cancer	0.000212	0.00452	CbGeAlD
Erlotinib—MKNK1—Estradiol—Ethinyl Estradiol—prostate cancer	0.000206	0.0933	CbGdCrCtD
Erlotinib—ABCG2—urethra—prostate cancer	0.000204	0.00434	CbGeAlD
Erlotinib—MAP2K5—lymph node—prostate cancer	0.0002	0.00426	CbGeAlD
Erlotinib—CYP1A2—renal system—prostate cancer	0.0002	0.00425	CbGeAlD
Erlotinib—CYP1A1—renal system—prostate cancer	0.000197	0.0042	CbGeAlD
Erlotinib—ALB—testis—prostate cancer	0.000196	0.00418	CbGeAlD
Erlotinib—CYP1A1—urethra—prostate cancer	0.000193	0.00412	CbGeAlD
Erlotinib—CYP3A5—renal system—prostate cancer	0.000193	0.0041	CbGeAlD
Erlotinib—Vandetanib—SRC—prostate cancer	0.000191	0.0472	CrCbGaD
Erlotinib—CYP1B1—testis—prostate cancer	0.00018	0.00384	CbGeAlD
Erlotinib—Vandetanib—KDR—prostate cancer	0.00018	0.0443	CrCbGaD
Erlotinib—ORM1—lymph node—prostate cancer	0.000162	0.00346	CbGeAlD
Erlotinib—ABCG2—bone marrow—prostate cancer	0.000157	0.00334	CbGeAlD
Erlotinib—SLCO2B1—lymph node—prostate cancer	0.000155	0.00331	CbGeAlD
Erlotinib—ABL1—lymph node—prostate cancer	0.000154	0.00328	CbGeAlD
Erlotinib—Vandetanib—VEGFA—prostate cancer	0.000152	0.0376	CrCbGaD
Erlotinib—ABCB1—prostate gland—prostate cancer	0.00015	0.0032	CbGeAlD
Erlotinib—ABL1—Levorphanol—Estrone—prostate cancer	0.000149	0.0675	CbGdCrCtD
Erlotinib—CYP3A4—renal system—prostate cancer	0.000144	0.00308	CbGeAlD
Erlotinib—ALB—lymph node—prostate cancer	0.000142	0.00303	CbGeAlD
Erlotinib—CYP2D6—renal system—prostate cancer	0.000142	0.00303	CbGeAlD
Erlotinib—CYP2C8—testis—prostate cancer	0.000138	0.00294	CbGeAlD
Erlotinib—ABCG2—testis—prostate cancer	0.000134	0.00286	CbGeAlD
Erlotinib—CYP1B1—lymph node—prostate cancer	0.000131	0.00278	CbGeAlD
Erlotinib—Vandetanib—EGFR—prostate cancer	0.000129	0.0317	CrCbGaD
Erlotinib—ABCB1—seminal vesicle—prostate cancer	0.000127	0.0027	CbGeAlD
Erlotinib—Gefitinib—EGFR—prostate cancer	0.000122	0.0301	CrCbGaD
Erlotinib—ABL1—Levorphanol—Estradiol—prostate cancer	0.000113	0.0512	CbGdCrCtD
Erlotinib—ABCB1—epithelium—prostate cancer	0.00011	0.00235	CbGeAlD
Erlotinib—Gefitinib—CYP3A5—prostate cancer	0.000103	0.0254	CrCbGaD
Erlotinib—ABCB1—renal system—prostate cancer	0.000102	0.00218	CbGeAlD
Erlotinib—ABCB1—urethra—prostate cancer	0.0001	0.00214	CbGeAlD
Erlotinib—ABCG2—lymph node—prostate cancer	9.72e-05	0.00207	CbGeAlD
Erlotinib—CYP1A1—lymph node—prostate cancer	9.23e-05	0.00197	CbGeAlD
Erlotinib—CYP2D6—testis—prostate cancer	9.19e-05	0.00196	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—prostate cancer	7.86e-05	0.0355	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	7.86e-05	0.0355	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	7.86e-05	0.0355	CbGdCrCtD
Erlotinib—ABCB1—bone marrow—prostate cancer	7.73e-05	0.00165	CbGeAlD
Erlotinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	7.27e-05	0.0329	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	7.27e-05	0.0329	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	7.27e-05	0.0329	CbGdCrCtD
Erlotinib—Gefitinib—CYP2C19—prostate cancer	7.02e-05	0.0173	CrCbGaD
Erlotinib—Gefitinib—CYP1A1—prostate cancer	6.99e-05	0.0172	CrCbGaD
Erlotinib—ABCB1—testis—prostate cancer	6.61e-05	0.00141	CbGeAlD
Erlotinib—ABCB1—lymph node—prostate cancer	4.79e-05	0.00102	CbGeAlD
Erlotinib—Vandetanib—CYP3A4—prostate cancer	4.7e-05	0.0116	CrCbGaD
Erlotinib—Gefitinib—CYP3A4—prostate cancer	4.47e-05	0.011	CrCbGaD
Erlotinib—Arthralgia—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Erlotinib—Loss of consciousness—Capecitabine—prostate cancer	3.29e-05	0.000289	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—prostate cancer	3.28e-05	0.000288	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—prostate cancer	3.28e-05	0.000288	CcSEcCtD
Erlotinib—Asthenia—Mitoxantrone—prostate cancer	3.28e-05	0.000287	CcSEcCtD
Erlotinib—Fatigue—Etoposide—prostate cancer	3.28e-05	0.000287	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—prostate cancer	3.27e-05	0.000287	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.27e-05	0.000287	CcSEcCtD
Erlotinib—Cough—Capecitabine—prostate cancer	3.27e-05	0.000287	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—prostate cancer	3.26e-05	0.000285	CcSEcCtD
Erlotinib—Pain—Etoposide—prostate cancer	3.25e-05	0.000285	CcSEcCtD
Erlotinib—Constipation—Etoposide—prostate cancer	3.25e-05	0.000285	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—prostate cancer	3.25e-05	0.000285	CcSEcCtD
Erlotinib—Dizziness—Estradiol—prostate cancer	3.24e-05	0.000284	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—prostate cancer	3.24e-05	0.000284	CcSEcCtD
Erlotinib—Myalgia—Capecitabine—prostate cancer	3.19e-05	0.00028	CcSEcCtD
Erlotinib—Chest pain—Capecitabine—prostate cancer	3.19e-05	0.00028	CcSEcCtD
Erlotinib—Arthralgia—Capecitabine—prostate cancer	3.19e-05	0.00028	CcSEcCtD
Erlotinib—Anxiety—Capecitabine—prostate cancer	3.18e-05	0.000279	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.17e-05	0.000278	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—prostate cancer	3.16e-05	0.000277	CcSEcCtD
Erlotinib—Oedema—Docetaxel—prostate cancer	3.16e-05	0.000277	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—prostate cancer	3.15e-05	0.000276	CcSEcCtD
Erlotinib—Infection—Docetaxel—prostate cancer	3.14e-05	0.000275	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—prostate cancer	3.14e-05	0.000275	CcSEcCtD
Erlotinib—Diarrhoea—Mitoxantrone—prostate cancer	3.13e-05	0.000274	CcSEcCtD
Erlotinib—Vomiting—Estradiol—prostate cancer	3.12e-05	0.000273	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—prostate cancer	3.11e-05	0.000272	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—prostate cancer	3.11e-05	0.000272	CcSEcCtD
Erlotinib—Shock—Docetaxel—prostate cancer	3.11e-05	0.000272	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—prostate cancer	3.1e-05	0.000271	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Erlotinib—Rash—Estradiol—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Erlotinib—Dermatitis—Estradiol—prostate cancer	3.09e-05	0.000271	CcSEcCtD
Erlotinib—Headache—Estradiol—prostate cancer	3.07e-05	0.000269	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—prostate cancer	3.07e-05	0.000269	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	3.06e-05	0.000269	CcSEcCtD
Erlotinib—Oedema—Capecitabine—prostate cancer	3.06e-05	0.000268	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—prostate cancer	3.04e-05	0.000266	CcSEcCtD
Erlotinib—Infection—Capecitabine—prostate cancer	3.04e-05	0.000266	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—prostate cancer	3.03e-05	0.000266	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—prostate cancer	3.01e-05	0.000264	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—prostate cancer	3.01e-05	0.000264	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—prostate cancer	3.01e-05	0.000264	CcSEcCtD
Erlotinib—Shock—Capecitabine—prostate cancer	3.01e-05	0.000264	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—prostate cancer	3e-05	0.000263	CcSEcCtD
Erlotinib—Nervous system disorder—Capecitabine—prostate cancer	3e-05	0.000263	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—prostate cancer	3e-05	0.000263	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—prostate cancer	3e-05	0.000263	CcSEcCtD
Erlotinib—Thrombocytopenia—Capecitabine—prostate cancer	2.99e-05	0.000262	CcSEcCtD
Erlotinib—Syncope—Prednisone—prostate cancer	2.99e-05	0.000262	CcSEcCtD
Erlotinib—Skin disorder—Capecitabine—prostate cancer	2.97e-05	0.00026	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—prostate cancer	2.96e-05	0.00026	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—prostate cancer	2.95e-05	0.000258	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—prostate cancer	2.94e-05	0.000258	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—prostate cancer	2.93e-05	0.000257	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.92e-05	0.000256	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—prostate cancer	2.92e-05	0.000255	CcSEcCtD
Erlotinib—Anorexia—Capecitabine—prostate cancer	2.92e-05	0.000255	CcSEcCtD
Erlotinib—Nausea—Estradiol—prostate cancer	2.91e-05	0.000255	CcSEcCtD
Erlotinib—Vomiting—Mitoxantrone—prostate cancer	2.91e-05	0.000255	CcSEcCtD
Erlotinib—Rash—Mitoxantrone—prostate cancer	2.88e-05	0.000252	CcSEcCtD
Erlotinib—Dermatitis—Mitoxantrone—prostate cancer	2.88e-05	0.000252	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.88e-05	0.000252	CcSEcCtD
Erlotinib—Headache—Mitoxantrone—prostate cancer	2.86e-05	0.000251	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—prostate cancer	2.86e-05	0.00025	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—prostate cancer	2.84e-05	0.000249	CcSEcCtD
Erlotinib—Myalgia—Prednisone—prostate cancer	2.84e-05	0.000249	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—prostate cancer	2.84e-05	0.000248	CcSEcCtD
Erlotinib—Anxiety—Prednisone—prostate cancer	2.83e-05	0.000248	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.82e-05	0.000247	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—prostate cancer	2.82e-05	0.000247	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—prostate cancer	2.8e-05	0.000246	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—prostate cancer	2.78e-05	0.000244	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—prostate cancer	2.78e-05	0.000243	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—prostate cancer	2.78e-05	0.000243	CcSEcCtD
Erlotinib—Insomnia—Capecitabine—prostate cancer	2.77e-05	0.000242	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—prostate cancer	2.75e-05	0.000241	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—prostate cancer	2.74e-05	0.00024	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Erlotinib—Asthenia—Etoposide—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Erlotinib—Dyspnoea—Capecitabine—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Erlotinib—Oedema—Prednisone—prostate cancer	2.72e-05	0.000239	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—prostate cancer	2.72e-05	0.000239	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—prostate cancer	2.72e-05	0.000238	CcSEcCtD
Erlotinib—Nausea—Mitoxantrone—prostate cancer	2.71e-05	0.000238	CcSEcCtD
Erlotinib—Infection—Prednisone—prostate cancer	2.71e-05	0.000237	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—prostate cancer	2.7e-05	0.000237	CcSEcCtD
Erlotinib—Constipation—Docetaxel—prostate cancer	2.7e-05	0.000237	CcSEcCtD
Erlotinib—Pain—Docetaxel—prostate cancer	2.7e-05	0.000237	CcSEcCtD
Erlotinib—Dyspepsia—Capecitabine—prostate cancer	2.69e-05	0.000236	CcSEcCtD
Erlotinib—Chills—Epirubicin—prostate cancer	2.69e-05	0.000236	CcSEcCtD
Erlotinib—Pruritus—Etoposide—prostate cancer	2.69e-05	0.000236	CcSEcCtD
Erlotinib—Shock—Prednisone—prostate cancer	2.68e-05	0.000235	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—prostate cancer	2.68e-05	0.000235	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—prostate cancer	2.67e-05	0.000234	CcSEcCtD
Erlotinib—Decreased appetite—Capecitabine—prostate cancer	2.66e-05	0.000233	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—prostate cancer	2.65e-05	0.000232	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—prostate cancer	2.65e-05	0.000232	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.64e-05	0.000231	CcSEcCtD
Erlotinib—Fatigue—Capecitabine—prostate cancer	2.64e-05	0.000231	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—prostate cancer	2.63e-05	0.00023	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—prostate cancer	2.62e-05	0.00023	CcSEcCtD
Erlotinib—Pain—Capecitabine—prostate cancer	2.62e-05	0.000229	CcSEcCtD
Erlotinib—Constipation—Capecitabine—prostate cancer	2.62e-05	0.000229	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—prostate cancer	2.61e-05	0.000229	CcSEcCtD
Erlotinib—Erythema—Epirubicin—prostate cancer	2.61e-05	0.000229	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—prostate cancer	2.6e-05	0.000228	CcSEcCtD
Erlotinib—Anorexia—Prednisone—prostate cancer	2.6e-05	0.000228	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—prostate cancer	2.59e-05	0.000227	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—prostate cancer	2.58e-05	0.000226	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—prostate cancer	2.57e-05	0.000225	CcSEcCtD
Erlotinib—Back pain—Epirubicin—prostate cancer	2.53e-05	0.000221	CcSEcCtD
Erlotinib—Dizziness—Etoposide—prostate cancer	2.51e-05	0.00022	CcSEcCtD
Erlotinib—Gastrointestinal pain—Capecitabine—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Erlotinib—Chills—Doxorubicin—prostate cancer	2.49e-05	0.000218	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—prostate cancer	2.48e-05	0.000217	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—prostate cancer	2.48e-05	0.000217	CcSEcCtD
Erlotinib—Insomnia—Prednisone—prostate cancer	2.46e-05	0.000216	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—prostate cancer	2.45e-05	0.000215	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—prostate cancer	2.43e-05	0.000213	CcSEcCtD
Erlotinib—Body temperature increased—Capecitabine—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Erlotinib—Abdominal pain—Capecitabine—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Erlotinib—Vomiting—Etoposide—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Erlotinib—Rash—Etoposide—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—prostate cancer	2.39e-05	0.00021	CcSEcCtD
Erlotinib—Headache—Etoposide—prostate cancer	2.38e-05	0.000209	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—prostate cancer	2.38e-05	0.000209	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—prostate cancer	2.37e-05	0.000208	CcSEcCtD
Erlotinib—Fatigue—Prednisone—prostate cancer	2.35e-05	0.000206	CcSEcCtD
Erlotinib—Syncope—Epirubicin—prostate cancer	2.34e-05	0.000205	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—prostate cancer	2.34e-05	0.000205	CcSEcCtD
Erlotinib—Constipation—Prednisone—prostate cancer	2.33e-05	0.000204	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—prostate cancer	2.29e-05	0.000201	CcSEcCtD
Erlotinib—Cough—Epirubicin—prostate cancer	2.28e-05	0.0002	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—prostate cancer	2.27e-05	0.000199	CcSEcCtD
Erlotinib—Nausea—Etoposide—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—prostate cancer	2.24e-05	0.000196	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—prostate cancer	2.22e-05	0.000195	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—prostate cancer	2.22e-05	0.000195	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—prostate cancer	2.22e-05	0.000195	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—prostate cancer	2.22e-05	0.000194	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.21e-05	0.000193	CcSEcCtD
Erlotinib—Asthenia—Capecitabine—prostate cancer	2.19e-05	0.000192	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—prostate cancer	2.17e-05	0.00019	CcSEcCtD
Erlotinib—Pruritus—Capecitabine—prostate cancer	2.16e-05	0.00019	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—prostate cancer	2.16e-05	0.000189	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—prostate cancer	2.15e-05	0.000189	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—prostate cancer	2.15e-05	0.000189	CcSEcCtD
Erlotinib—Oedema—Epirubicin—prostate cancer	2.13e-05	0.000187	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—prostate cancer	2.12e-05	0.000186	CcSEcCtD
Erlotinib—Infection—Epirubicin—prostate cancer	2.12e-05	0.000185	CcSEcCtD
Erlotinib—Cough—Doxorubicin—prostate cancer	2.11e-05	0.000185	CcSEcCtD
Erlotinib—Shock—Epirubicin—prostate cancer	2.1e-05	0.000184	CcSEcCtD
Erlotinib—Diarrhoea—Capecitabine—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—prostate cancer	2.07e-05	0.000181	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—prostate cancer	2.05e-05	0.00018	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.04e-05	0.000179	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—prostate cancer	2.03e-05	0.000178	CcSEcCtD
Erlotinib—Dizziness—Capecitabine—prostate cancer	2.02e-05	0.000177	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—prostate cancer	2.01e-05	0.000176	CcSEcCtD
Erlotinib—Rash—Docetaxel—prostate cancer	1.99e-05	0.000175	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—prostate cancer	1.99e-05	0.000174	CcSEcCtD
Erlotinib—Headache—Docetaxel—prostate cancer	1.98e-05	0.000173	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—prostate cancer	1.97e-05	0.000173	CcSEcCtD
Erlotinib—Infection—Doxorubicin—prostate cancer	1.96e-05	0.000172	CcSEcCtD
Erlotinib—Asthenia—Prednisone—prostate cancer	1.95e-05	0.000171	CcSEcCtD
Erlotinib—Vomiting—Capecitabine—prostate cancer	1.94e-05	0.00017	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.94e-05	0.00017	CcSEcCtD
Erlotinib—Shock—Doxorubicin—prostate cancer	1.94e-05	0.00017	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Rash—Capecitabine—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Pruritus—Prednisone—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Dermatitis—Capecitabine—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Erlotinib—Headache—Capecitabine—prostate cancer	1.92e-05	0.000168	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—prostate cancer	1.92e-05	0.000168	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—prostate cancer	1.9e-05	0.000166	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—prostate cancer	1.88e-05	0.000165	CcSEcCtD
Erlotinib—Nausea—Docetaxel—prostate cancer	1.88e-05	0.000164	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—prostate cancer	1.88e-05	0.000164	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—prostate cancer	1.86e-05	0.000163	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—prostate cancer	1.85e-05	0.000162	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.84e-05	0.000161	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—prostate cancer	1.84e-05	0.000161	CcSEcCtD
Erlotinib—Pain—Epirubicin—prostate cancer	1.82e-05	0.00016	CcSEcCtD
Erlotinib—Constipation—Epirubicin—prostate cancer	1.82e-05	0.00016	CcSEcCtD
Erlotinib—Nausea—Capecitabine—prostate cancer	1.82e-05	0.000159	CcSEcCtD
Erlotinib—Dizziness—Prednisone—prostate cancer	1.8e-05	0.000158	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.8e-05	0.000157	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—prostate cancer	1.78e-05	0.000156	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—prostate cancer	1.76e-05	0.000154	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.74e-05	0.000153	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—prostate cancer	1.74e-05	0.000152	CcSEcCtD
Erlotinib—Vomiting—Prednisone—prostate cancer	1.73e-05	0.000152	CcSEcCtD
Erlotinib—Rash—Prednisone—prostate cancer	1.72e-05	0.000151	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—prostate cancer	1.72e-05	0.00015	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—prostate cancer	1.71e-05	0.00015	CcSEcCtD
Erlotinib—Headache—Prednisone—prostate cancer	1.71e-05	0.00015	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.7e-05	0.000149	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—prostate cancer	1.7e-05	0.000149	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—prostate cancer	1.69e-05	0.000148	CcSEcCtD
Erlotinib—Pain—Doxorubicin—prostate cancer	1.69e-05	0.000148	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—prostate cancer	1.68e-05	0.000148	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—prostate cancer	1.68e-05	0.000148	CcSEcCtD
Erlotinib—Nausea—Prednisone—prostate cancer	1.62e-05	0.000142	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.61e-05	0.000141	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—prostate cancer	1.56e-05	0.000137	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—prostate cancer	1.56e-05	0.000137	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—prostate cancer	1.53e-05	0.000134	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—prostate cancer	1.51e-05	0.000132	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—prostate cancer	1.46e-05	0.000128	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—prostate cancer	1.41e-05	0.000124	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—prostate cancer	1.41e-05	0.000123	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—prostate cancer	1.39e-05	0.000122	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—prostate cancer	1.35e-05	0.000119	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—prostate cancer	1.35e-05	0.000118	CcSEcCtD
Erlotinib—Rash—Epirubicin—prostate cancer	1.34e-05	0.000118	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—prostate cancer	1.34e-05	0.000118	CcSEcCtD
Erlotinib—Headache—Epirubicin—prostate cancer	1.33e-05	0.000117	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—prostate cancer	1.3e-05	0.000114	CcSEcCtD
Erlotinib—Nausea—Epirubicin—prostate cancer	1.27e-05	0.000111	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—prostate cancer	1.25e-05	0.00011	CcSEcCtD
Erlotinib—Rash—Doxorubicin—prostate cancer	1.24e-05	0.000109	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—prostate cancer	1.24e-05	0.000109	CcSEcCtD
Erlotinib—Headache—Doxorubicin—prostate cancer	1.24e-05	0.000108	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—prostate cancer	1.17e-05	0.000103	CcSEcCtD
Erlotinib—CYP3A4—Metabolism—GNG5—prostate cancer	7.73e-07	7.67e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—prostate cancer	7.7e-07	7.65e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—prostate cancer	7.7e-07	7.64e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAV1—prostate cancer	7.69e-07	7.64e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ERCC2—prostate cancer	7.68e-07	7.63e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—prostate cancer	7.68e-07	7.63e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—prostate cancer	7.68e-07	7.62e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—prostate cancer	7.64e-07	7.59e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—prostate cancer	7.64e-07	7.59e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—prostate cancer	7.63e-07	7.58e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—prostate cancer	7.62e-07	7.57e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ITPR1—prostate cancer	7.62e-07	7.57e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RXRA—prostate cancer	7.62e-07	7.56e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—prostate cancer	7.62e-07	7.56e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—prostate cancer	7.57e-07	7.51e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—prostate cancer	7.54e-07	7.48e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2E1—prostate cancer	7.5e-07	7.45e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—prostate cancer	7.49e-07	7.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA3—prostate cancer	7.44e-07	7.39e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—prostate cancer	7.42e-07	7.37e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NQO1—prostate cancer	7.42e-07	7.36e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—prostate cancer	7.41e-07	7.35e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—prostate cancer	7.4e-07	7.35e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—prostate cancer	7.38e-07	7.32e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—prostate cancer	7.37e-07	7.32e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COMT—prostate cancer	7.34e-07	7.28e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TH—prostate cancer	7.31e-07	7.26e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—prostate cancer	7.3e-07	7.25e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—prostate cancer	7.28e-07	7.23e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—prostate cancer	7.27e-07	7.22e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—prostate cancer	7.27e-07	7.21e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.26e-07	7.21e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP3A4—prostate cancer	7.23e-07	7.18e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—prostate cancer	7.22e-07	7.17e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—prostate cancer	7.2e-07	7.15e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.2e-07	7.14e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ITPR1—prostate cancer	7.18e-07	7.13e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—prostate cancer	7.18e-07	7.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—prostate cancer	7.12e-07	7.07e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—prostate cancer	7.12e-07	7.07e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1B1—prostate cancer	7.11e-07	7.06e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGDS—prostate cancer	7.1e-07	7.05e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARA—prostate cancer	7.09e-07	7.04e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JAK2—prostate cancer	7.07e-07	7.02e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2C19—prostate cancer	7.06e-07	7.01e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARA—prostate cancer	7.05e-07	7e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—prostate cancer	7.01e-07	6.96e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—LPL—prostate cancer	6.99e-07	6.94e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—prostate cancer	6.95e-07	6.9e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.94e-07	6.89e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—prostate cancer	6.93e-07	6.88e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—prostate cancer	6.9e-07	6.85e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—prostate cancer	6.89e-07	6.84e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—prostate cancer	6.89e-07	6.84e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ACHE—prostate cancer	6.89e-07	6.84e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GGT1—prostate cancer	6.89e-07	6.84e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—prostate cancer	6.88e-07	6.83e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—prostate cancer	6.87e-07	6.82e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.81e-07	6.76e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—prostate cancer	6.8e-07	6.75e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—prostate cancer	6.79e-07	6.74e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—prostate cancer	6.79e-07	6.74e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOA1—prostate cancer	6.78e-07	6.73e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—prostate cancer	6.75e-07	6.7e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—prostate cancer	6.75e-07	6.7e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—prostate cancer	6.72e-07	6.68e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—prostate cancer	6.71e-07	6.66e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—prostate cancer	6.71e-07	6.66e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—prostate cancer	6.69e-07	6.65e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—prostate cancer	6.68e-07	6.64e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—prostate cancer	6.66e-07	6.61e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—INS—prostate cancer	6.63e-07	6.58e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—prostate cancer	6.62e-07	6.58e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.62e-07	6.57e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—prostate cancer	6.62e-07	6.57e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PRKACB—prostate cancer	6.59e-07	6.54e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—LPL—prostate cancer	6.59e-07	6.54e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—prostate cancer	6.56e-07	6.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.52e-07	6.47e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CREBBP—prostate cancer	6.5e-07	6.45e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—prostate cancer	6.47e-07	6.43e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RXRA—prostate cancer	6.45e-07	6.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—prostate cancer	6.45e-07	6.4e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.36e-07	6.32e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—prostate cancer	6.36e-07	6.31e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—prostate cancer	6.36e-07	6.31e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.33e-07	6.28e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—prostate cancer	6.33e-07	6.28e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—prostate cancer	6.31e-07	6.26e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	6.3e-07	6.25e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—prostate cancer	6.29e-07	6.25e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.27e-07	6.23e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—INS—prostate cancer	6.27e-07	6.22e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	6.23e-07	6.18e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COMT—prostate cancer	6.21e-07	6.17e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA2—prostate cancer	6.21e-07	6.17e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—prostate cancer	6.19e-07	6.14e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—prostate cancer	6.17e-07	6.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARA—prostate cancer	6.17e-07	6.13e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—prostate cancer	6.17e-07	6.13e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—prostate cancer	6.16e-07	6.12e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	6.16e-07	6.12e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CREBBP—prostate cancer	6.14e-07	6.09e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—prostate cancer	6.13e-07	6.09e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ITPR1—prostate cancer	6.09e-07	6.04e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—prostate cancer	6.07e-07	6.03e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—prostate cancer	6.05e-07	6.01e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—prostate cancer	6.03e-07	5.99e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—prostate cancer	6.01e-07	5.97e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.98e-07	5.94e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	5.95e-07	5.91e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—prostate cancer	5.93e-07	5.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.93e-07	5.88e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—prostate cancer	5.84e-07	5.8e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—prostate cancer	5.83e-07	5.79e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—prostate cancer	5.82e-07	5.78e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARA—prostate cancer	5.82e-07	5.78e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—prostate cancer	5.82e-07	5.77e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	5.81e-07	5.77e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—prostate cancer	5.8e-07	5.76e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—prostate cancer	5.8e-07	5.76e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.79e-07	5.75e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—prostate cancer	5.75e-07	5.71e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—INS—prostate cancer	5.74e-07	5.7e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NQO1—prostate cancer	5.72e-07	5.68e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—INS—prostate cancer	5.71e-07	5.67e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—prostate cancer	5.68e-07	5.64e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—prostate cancer	5.68e-07	5.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—prostate cancer	5.66e-07	5.62e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TH—prostate cancer	5.64e-07	5.6e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CREBBP—prostate cancer	5.63e-07	5.59e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—prostate cancer	5.6e-07	5.56e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CREBBP—prostate cancer	5.59e-07	5.55e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—LPL—prostate cancer	5.58e-07	5.54e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—prostate cancer	5.53e-07	5.49e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—prostate cancer	5.49e-07	5.46e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.49e-07	5.45e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—prostate cancer	5.47e-07	5.43e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.39e-07	5.35e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—prostate cancer	5.38e-07	5.34e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—prostate cancer	5.38e-07	5.34e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	5.37e-07	5.33e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—prostate cancer	5.34e-07	5.31e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—prostate cancer	5.33e-07	5.3e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—prostate cancer	5.32e-07	5.28e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GGT1—prostate cancer	5.31e-07	5.28e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—prostate cancer	5.3e-07	5.27e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—prostate cancer	5.29e-07	5.25e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—prostate cancer	5.24e-07	5.2e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA1—prostate cancer	5.23e-07	5.2e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—prostate cancer	5.19e-07	5.15e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—prostate cancer	5.17e-07	5.14e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—prostate cancer	5.17e-07	5.13e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.16e-07	5.12e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—prostate cancer	5.07e-07	5.04e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—prostate cancer	5.04e-07	5e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—prostate cancer	5.03e-07	4.99e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—prostate cancer	5.02e-07	4.99e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—prostate cancer	5.02e-07	4.98e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—prostate cancer	5.01e-07	4.97e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—INS—prostate cancer	5e-07	4.97e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.98e-07	4.95e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RXRA—prostate cancer	4.98e-07	4.94e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARA—prostate cancer	4.93e-07	4.89e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CREBBP—prostate cancer	4.9e-07	4.87e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—prostate cancer	4.82e-07	4.78e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—prostate cancer	4.81e-07	4.77e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COMT—prostate cancer	4.8e-07	4.76e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—prostate cancer	4.77e-07	4.74e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—prostate cancer	4.77e-07	4.74e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—INS—prostate cancer	4.72e-07	4.68e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ITPR1—prostate cancer	4.7e-07	4.66e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—prostate cancer	4.65e-07	4.62e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—prostate cancer	4.65e-07	4.61e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—prostate cancer	4.64e-07	4.61e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—prostate cancer	4.63e-07	4.6e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—prostate cancer	4.62e-07	4.59e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CREBBP—prostate cancer	4.62e-07	4.59e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—prostate cancer	4.61e-07	4.57e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—prostate cancer	4.58e-07	4.55e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—prostate cancer	4.57e-07	4.54e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—prostate cancer	4.45e-07	4.42e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—prostate cancer	4.44e-07	4.41e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.43e-07	4.4e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—prostate cancer	4.42e-07	4.39e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—prostate cancer	4.4e-07	4.37e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—prostate cancer	4.39e-07	4.36e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—prostate cancer	4.39e-07	4.36e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—prostate cancer	4.38e-07	4.35e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.38e-07	4.35e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LPL—prostate cancer	4.31e-07	4.27e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.22e-07	4.19e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—prostate cancer	4.18e-07	4.15e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.16e-07	4.13e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—prostate cancer	4.14e-07	4.11e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—prostate cancer	4.12e-07	4.09e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—prostate cancer	4.1e-07	4.07e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	4.09e-07	4.06e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—prostate cancer	4.05e-07	4.02e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—prostate cancer	4.02e-07	3.99e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—prostate cancer	4.01e-07	3.99e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—prostate cancer	4e-07	3.97e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—INS—prostate cancer	4e-07	3.97e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—prostate cancer	3.96e-07	3.93e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CREBBP—prostate cancer	3.91e-07	3.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—prostate cancer	3.88e-07	3.85e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—prostate cancer	3.83e-07	3.8e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.82e-07	3.79e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—prostate cancer	3.81e-07	3.78e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARA—prostate cancer	3.8e-07	3.78e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—prostate cancer	3.78e-07	3.76e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—prostate cancer	3.73e-07	3.7e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.71e-07	3.68e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—prostate cancer	3.62e-07	3.6e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—prostate cancer	3.58e-07	3.55e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—prostate cancer	3.5e-07	3.48e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—prostate cancer	3.5e-07	3.48e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—prostate cancer	3.34e-07	3.32e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—prostate cancer	3.34e-07	3.31e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—prostate cancer	3.3e-07	3.28e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	3.27e-07	3.25e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.26e-07	3.23e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.23e-07	3.21e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—prostate cancer	3.2e-07	3.18e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—prostate cancer	3.15e-07	3.12e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—prostate cancer	3.09e-07	3.07e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—INS—prostate cancer	3.08e-07	3.06e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CREBBP—prostate cancer	3.02e-07	3e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.86e-07	2.84e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—prostate cancer	2.83e-07	2.81e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—prostate cancer	2.82e-07	2.8e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—prostate cancer	2.79e-07	2.77e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—prostate cancer	2.7e-07	2.68e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—prostate cancer	2.67e-07	2.65e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—prostate cancer	2.66e-07	2.65e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—prostate cancer	2.53e-07	2.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.5e-07	2.48e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—prostate cancer	2.47e-07	2.46e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—prostate cancer	2.47e-07	2.45e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.33e-07	2.31e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—prostate cancer	2.32e-07	2.3e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—prostate cancer	2.3e-07	2.29e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—prostate cancer	2.16e-07	2.14e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—prostate cancer	2.06e-07	2.04e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—prostate cancer	2.02e-07	2e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.97e-07	1.96e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—prostate cancer	1.9e-07	1.89e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—prostate cancer	1.61e-07	1.6e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.52e-07	1.51e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—prostate cancer	1.24e-07	1.23e-06	CbGpPWpGaD
